Results of meta-analysisa
Overall | DED | SPED | Intergroup Heterogeneity | |
---|---|---|---|---|
Efficacy outcomes | ||||
Technical success | 99.6% (98.6%–99.8%) I2 = 33.0% P = .165 | 100% (99.2%–100%) I2 = 0.00% P = .487 | 99.2% (97.2%–100%) I2 = 54.4% P = .087 | P = .165 |
Aneurysm occlusion rate (6 mo) | 80.5%b (74.5%–86.0%) I2 = 70.8% P = .000 | 78.9% (74.3%–83.1%) I2 = 0.00% P = .559 | 82.7%b (73.4%–90.4%) I2 = 75.3% P = .000 | P = .420 |
Aneurysm occlusion rate (12 mo) | 85.6% (80.6%–90.0%) I2 = 0.00% P = .744 | 87.8% (80.9%–93.5%) NA | 83.2% (75.8%–89.6%) NA | P = .329 |
Safety outcomes | ||||
Mortality rate | 1.0% (0.3%–1.9%) I2 = 0.00% P = .608 | 1.3% (0.2%–3.1%) I2 = 5.47% P = .366 | 0.8% (0.1%–1.9%) I2 = 0.00% P = .675 | P = .410 |
Morbidity rate | 6.0% (4.5%–7.7%) I2 = 0.00% P = .857 | 6.3% (3.9%–9.1%) I2 = 0.00% P = .618 | 5.8% (3.9%–8.1%) I2 = 0.00% P = .710 | P = .725 |
Total ischemia rate | 6.7%b (4.1%–10.1%) I2 = 61.9% P = .010 | 8.3%b (2.9%–15.7%) I2 = 75.1% P = .007 | 6.3% (3.2%–10.2%) I2 = 50.1% P = .111 | P = .548 |
Serious ischemia rate | 1.8% (0.8%–3.0%) I2 = 12.1% P = .335 | 2.5% (1.0%–4.6%) I2 = 0.00% P = .685 | 1.2% (0.1%–3.2%) I2 = 37.0% P = .190 | P = .240 |